

Around the world of U.S. healthcare in 360 words or less

Center for Healthcare Regulatory Insight

January 29, 2021 | Issue 157

Editor's note

This note is produced every Friday by the <u>KPMG Center for Healthcare</u> <u>Regulatory Insight</u> and is intended to be short and succinct, no more than 360 words, to provide a digestible bite of healthcare and life sciences news from the past week. Please share this email with colleagues and other interested individuals, and encourage them to <u>subscribe to our mailing list</u> <u>here</u>.

We welcome your feedback. Let us know if KPMG can help. Please <u>reply</u> <u>here to me</u>, **Larry Kocot**, principal and national leader, KPMG Center for Healthcare Regulatory Insight or simply reply to this email with any comments or requests.

Subscribe here 🏑

Special Supplement: COVID-19 News

In light of the continuing daily volume of COVID-19 activity and news, we have summarized <u>COVID-19 news for the week in this special supplement</u>.





Healthcare regulatory news

President Biden <u>signed an Executive Order</u> to open a healthcare.gov special enrollment period (February 15-May 15) with <u>\$50M in outreach</u> and <u>reconsider ACA and Medicaid rules and policies</u> that undermine preexisting condition protections, demonstrations/waivers that reduce coverage, and policies presenting barriers to enrollment or reducing affordability... KFF <u>estimated 8.9 of 15M uninsured Americans</u> could be eligible for no-premium bronze plans (4M) or subsidized insurance (4.9M).

HHS paused drug rebate, Part D e-prescribing, and organ procurement organization final rules... OMB withdrew several FDA rules and guidance documents, including for cannabidiol, antimicrobial drugs, and regulation of tobacco products... HHS withdrew proposed rules affecting in-center dialysis coverage, allowing seniors to opt out of Medicare Part A, and increasing oversight of accrediting organizations... HHS will cancel Trump Administration practice guidelines broadening which physicians could prescribe buprenorphine... GAO previously determined that effective dates for <u>Stark Law</u> and <u>Antikick-back Statute</u> rules violated the Congressional Review Act and could be subject to delay or withdrawal.

FDA approved <u>Exelixis' renal cell carcinoma treatment</u> in conjunction with Opdivo... FDA approved Aurinia Pharmaceuticals' <u>lupus nephritis</u> <u>treatment</u>... FDA released a <u>five-pronged strategy</u> for use and regulation of AI.

The Office of the Special Counsel reported that funds intended for BARDA health emergency response efforts were diverted to pay for other expenses in ASPR going back to the Obama Administration.

0



Healthcare law and policy news

President Biden selected nurse Susan Orsega as Acting Surgeon General.

AthenaHealth <u>will pay \$18.25M</u> to settle kickback allegations... PhRMA <u>sued to block implementation</u> of the 340B dispute resolution process rule... FTC <u>sued Endo International and Impax Laboratories</u> for alleged antitrust law violations related to an opioid.

KPMG, EBG, and FP reported <u>a record number of announced/closed</u> <u>healthcare deals</u> in 2020 (1,936)... Henry Ford Health System and Michigan State University <u>signed a 30-year affiliation agreement</u>... MultiPlan will <u>acquire Discovery Health Partners (\$155M)</u>... Verana Health will <u>collaborate with Janssen Research & Development</u> on data-driven approaches for ophthalmology and urology treatment.

Colorado is <u>soliciting vendors to help import</u> prescription drugs from Canada... CivicaRx will <u>build a manufacturing facility</u> in Virginia to produce sterile injectable medications. RAND reported that US prescription <u>drug prices are 256% higher</u> than 32 other countries; brand-name drug prices are 344% higher.

0



Questions or comments, please send to <u>ushcinsight@kpmg.com</u>.

Succeeding in the new reality

Visit the COVID-19 resource center for KPMG analysis, insights, and perspectives.



Privacy | Legal

You have received this message from KPMG LLP. If you wish to unsubscribe from Around the world of U.S. healthcare in 360 words or less, please click here. If you wish to unsubscribe from all KPMG communications, please click here.

KPMG LLP, 3 Chestnut Ridge Road, Montvale, NJ 07645

© 2021 KPMG LLP, a Delaware limited liability partnership and a member firm of the KPMG global organization of independent member firms affiliated with KPMG International Limited, a private English company limited by guarantee. All rights reserved. NDP131714-1A

The KPMG name and logo are trademarks used under license by the independent member firms of the KPMG global organization.



COVID-19 News Supplement

Center for Healthcare Regulatory Insight



COVID-19 by the Numbers

There are now over 25.7 million confirmed COVID-19 cases in the US, with a <u>death toll over 430,000</u>... The average number of cases/day <u>fell in 41 states over the past week</u>, down 16% total to 165,000 cases/day... CDC forecasted <u>between 479,000 and 514,000 US deaths</u> by February 20... A STAT analysis found that "excess deaths unattributed to COVID-19" are <u>far more common in strong Trump-supporting</u> <u>counties</u> across the country, suggesting that COVID-related deaths are likely to be undercounted in those areas.

Minnesota reported the <u>first US case of a COVID-19 variant</u> first identified in Brazil... South Carolina reported the first US cases of a <u>COVID-19 variant first identified in South Africa</u>; more than <u>30 countries have now detected</u> the variant... A CDC study found <u>low incidence of COVID-19 spread in school</u> <u>classrooms</u> when safety precautions, such as mask wearing and "student cohorting," are followed.

27.3 million COVID-19 <u>vaccine doses have been administered in the US</u>, 56% of total doses distributed to states... CDC <u>data show</u> that <u>sixteen states have used less than half</u> of their distributed COVID-19 vaccines... Some states are <u>rerouting a portion of unused COVID-19 vaccines</u> from nursing homes.

CDC reported that as of January 10th, there have been <u>1,266 total "adverse events" after receipt of</u> <u>Moderna's COVID-19 vaccine</u>, 108 possible "severe allergic reactions," and 10 cases of anaphylaxis (or just 2.5 per million doses administered).

Executive and Administrative Action

The White House <u>held the first of its planned</u> thrice weekly COVID-19 response press briefings... White House COVID-19 Response Coordinator Jeff Zients announced that HHS would <u>amend rules under the</u> <u>Public Readiness and Emergency Preparedness (PREP) Act to permit</u> recently-retired or inactive doctors and nurses to administer COVID-19 vaccines and to permit providers to administer vaccines across state lines.

President Biden issued a <u>COVID-related travel ban</u> from South Africa and reinstated restrictions from Brazil, the U.K., and dozens of European countries... The Administration is considering <u>expanding</u> <u>mandatory COVID-19 testing to passengers</u> on US domestic flights.

President Biden signed an executive order <u>directing HHS to issue guidance</u> on "best practices for advancing cultural competency, language access, and sensitivity towards Asian Americans and Pacific Islanders" through the federal government's COVID-19 response.

Acting HHS Secretary Norris Cochran <u>told governors in a letter</u> that the COVID-19 public health emergency, including the 6.2% Medicaid FMAP increase, will likely extend through 2021. GAO <u>issued 13 recommendations</u> to federal agencies to improve COVID-19 response, including those related to collection of data on COVID-19 testing, addressing supply chain gaps, and vaccine distribution.

Healthcare Regulatory News

FDA issued <u>an import alert on all alcohol-based sanitizers from Mexico</u> due to concerns about methanol contamination.

FDA is considering <u>developing a new pathway for potential changes</u> to emergency-use-authorized COVID-19 products, including vaccines, should changes be needed to address new virus variants.

Healthcare Law, Business, and Policy News

The House Energy and Commerce Committee is working with the Biden Administration to develop health-related components of a COVID-19 relief package; the Health subcommittee scheduled a February 3 hearing on accelerating delivery of vaccines, expanding testing, and addressing supply shortages... Democratic leaders are moving forward on plans to use reconciliation if they fail to gain Republican support for a relief package.

Oxfam International reported that the <u>COVID-19 pandemic could increase economic inequality</u> in nearly every country... Bill and Melinda Gates warned that the lasting <u>legacy of the pandemic could be</u> <u>"immunity inequality"</u> resulting from inequitable access to COVID-19 vaccines.

41% of US adults in a KFF poll <u>say they will get the COVID-19 vaccine as soon as possible</u>, up from 34% in December... KFF analysis found that the <u>country would need to administer 2.4 million COVID-19</u> <u>vaccines doses/day</u> to reach herd immunity (70% of the population) by July 4.

GISAID <u>data show</u> that the US is <u>lagging behind other countries in genome sequencing</u> (per 1,000 COVID-19 cases) used to detect virus variants; CDC Director Rochelle Walensky said that the federal government <u>would increase surveillance</u> of COVID-19 variants.

HCA formed a <u>consortium with AHRQ and several institutions</u>, including medical colleges, to accelerate COVID-19 research using its database of COVID-19 hospital care and outcomes... Google <u>committed</u> <u>\$150 million to COVID-19 vaccine education</u>, will use some of its building and parking lots for vaccination clinics, and will partner with One Medical to open vaccination sites... 23andMe launched <u>a "severity</u> <u>calculator"</u> to help predict an individual's risk of developing a severe case of COVID-19.

Surveillance, Testing, and Treatment

President Biden increased the <u>Administration's goal of vaccines administered in his first 100 days</u> to 150 million; Biden advisors cautioned that the <u>vaccine will not be available by this spring</u> to everyone who wants it.

The Administration is <u>considering using the Defense Production Act to require drug manufacturers</u> to produce already-authorized COVID-19 vaccines from other companies... Novartis is in <u>discussions to</u> <u>support such an effort</u>.

The Defense Department is reviewing <u>a FEMA request to help administer COVID-19 vaccines</u> at locations across the country.

The federal government <u>plans to purchase 100 million more doses each</u> of Pfizer-BioNTech's and Moderna's COVID-19 vaccine... The Administration will <u>increase COVID-19 vaccine shipments to</u> <u>jurisdictions</u> by 16% starting next week, increasing from 8.6 million to 10 million total doses.

Pfizer will provide the federal government with fewer vials of its COVID-19 vaccine than previously expected, given changes to its emergency use authorization reflecting the fact that vials contain six, not five, doses; however, <u>sufficient supply of syringes to extract</u> the "extra" dose does not currently exist... Pfizer will <u>supply the US with 200 million doses</u> of its vaccine by the end of May, two months sooner than expected, as a result of the "extra" doses... Pfizer and BioNTech will <u>provide 40 million doses</u> of its COVID-19 vaccine to COVAX...Pfizer completed <u>enrollment of more than 2,000 children ages 12-15</u> in a study of its COVID-19 vaccine.

Moderna reported that it COVID-19 vaccine <u>produced neutralizing impacts against virus strains</u> identified in the UK and South Africa and that it was developing booster doses to increasing neutralizing impacts against emerging strains.

Johnson & Johnson (J&J) reported that its <u>single-dose COVID-19 vaccine is 66% effective overall</u>, including 72% effective in a US trial and 57% effective in South Africa; the vaccine reduced several disease by 85%... J&J's head of R&D noted that the <u>vaccine's effectiveness</u>, relative to vaccines from <u>Pfizer-BioNTech and Moderna</u>, could have been impacted by the increasing incidence of potentially resistant variants that were not as present during previously completed clinical trials... J&J hopes to receive <u>emergency use authorization and administer 100 million doses by June</u>.

Novavax reported that its <u>COVID-19 vaccine is 89% effective</u> in preliminary clinical trial results, but appears less effective against new virus variants.

Merck announced it would <u>stop development of two experimental COVID-19 vaccines</u> due to inadequate immune responses.

AstraZeneca will conduct a study on the optimal interval between two doses of its COVID-19 vaccine.

NIH is leveraging the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) publicprivate partnership to <u>better study how vaccines and monoclonal antibody treatments perform</u> against <u>new COVID-19 variants</u>.

Regeneron reported that its monoclonal antibody treatments prevented COVID-19 in a clinical trial.